-$0.25 Earnings Per Share Expected for 10x Genomics, Inc. (NASDAQ:TXG) This Quarter

Equities research analysts expect that 10x Genomics, Inc. (NASDAQ:TXG) will post ($0.25) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for 10x Genomics’ earnings, with estimates ranging from ($0.35) to ($0.15). 10x Genomics posted earnings per share of ($0.22) in the same quarter last year, which would suggest a negative year-over-year growth rate of 13.6%. The company is scheduled to announce its next quarterly earnings report on Monday, May 10th.

On average, analysts expect that 10x Genomics will report full year earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($0.90) to ($0.57). For the next year, analysts expect that the firm will post earnings of ($0.13) per share, with EPS estimates ranging from ($0.49) to $0.21. Zacks’ earnings per share averages are an average based on a survey of research firms that follow 10x Genomics.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Tuesday, February 16th. The company reported ($3.87) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($3.59). The company had revenue of $112.22 million for the quarter, compared to analysts’ expectations of $101.20 million. 10x Genomics had a negative net margin of 51.27% and a negative return on equity of 19.98%.

A number of equities analysts have weighed in on TXG shares. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upped their price target on shares of 10x Genomics from $165.00 to $195.00 in a research report on Wednesday, December 16th. Smith Barney Citigroup upped their price target on shares of 10x Genomics from $165.00 to $195.00 in a research report on Wednesday, December 16th. Morgan Stanley upped their price target on shares of 10x Genomics from $145.00 to $215.00 and gave the stock an “overweight” rating in a research report on Thursday, February 25th. Citigroup upped their target price on shares of 10x Genomics from $195.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, February 25th. Finally, William Blair started coverage on shares of 10x Genomics in a research report on Monday, March 22nd. They set an “outperform” rating for the company. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $183.70.

In other news, Director Sridhar Kosaraju sold 1,500 shares of the company’s stock in a transaction dated Tuesday, March 23rd. The shares were sold at an average price of $174.63, for a total value of $261,945.00. Following the transaction, the director now directly owns 2,833 shares in the company, valued at $494,726.79. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John R. Stuelpnagel sold 7,500 shares of the company’s stock in a transaction dated Tuesday, January 19th. The stock was sold at an average price of $178.76, for a total transaction of $1,340,700.00. Following the completion of the transaction, the director now owns 479,591 shares in the company, valued at $85,731,687.16. The disclosure for this sale can be found here. In the last three months, insiders sold 144,416 shares of company stock worth $25,731,264. Insiders own 13.28% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. DekaBank Deutsche Girozentrale bought a new position in 10x Genomics during the 4th quarter worth about $496,000. Dimensional Fund Advisors LP boosted its holdings in shares of 10x Genomics by 128.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 13,622 shares of the company’s stock valued at $1,929,000 after buying an additional 7,671 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $142,000. UBS Asset Management Americas Inc. boosted its holdings in shares of 10x Genomics by 41.0% in the 4th quarter. UBS Asset Management Americas Inc. now owns 621,108 shares of the company’s stock valued at $87,949,000 after buying an additional 180,577 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $1,189,000. Institutional investors own 68.84% of the company’s stock.

Shares of NASDAQ TXG opened at $185.34 on Thursday. The firm has a market capitalization of $20.16 billion, a price-to-earnings ratio of -137.29 and a beta of 1.39. 10x Genomics has a 12-month low of $59.36 and a 12-month high of $201.70. The firm has a 50 day moving average of $174.12 and a 200 day moving average of $158.90.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products.

Featured Story: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on 10x Genomics (TXG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.